Miracle Therapeutics: Negotiating an IP License (A) Custom Case Solution & Analysis

1. Evidence Brief: Miracle Therapeutics IP Negotiation

Prepared by: Business Case Data Researcher

Financial Metrics

• Cash Position: Miracle Therapeutics (MT) maintains approximately $4.2M in liquid assets as of the case date (Paragraph 4).
• Burn Rate: Monthly operational expenses average $450,000, providing a runway of roughly 9 months without new capital (Paragraph 5).
• R&D Investment: Cumulative spend on MT-101 development totals $12.8M to date (Exhibit 2).
• Proposed Deal Terms: Initial offer from BigPharma includes a $10M upfront payment and a tiered royalty starting at 4% (Exhibit 4).
• Valuation Gap: MT internal projections value the IP at $45M; BigPharma valuation models suggest $28M (Paragraph 12).

Operational Facts

• Product Status: MT-101 has completed Phase IIa trials with statistically significant efficacy in 62% of the test cohort (Paragraph 8).
• Patent Protection: Core composition-of-matter patent expires in 11 years; secondary method-of-use patents extend to 15 years (Exhibit 3).
• Manufacturing: MT currently relies on a single-source contract manufacturing organization (CMO) in Switzerland (Paragraph 15).
• Regulatory Path: Orphan drug designation granted by the FDA, potentially accelerating the approval timeline by 18 months (Paragraph 9).

Stakeholder Positions

• Dr. Sarah Miller (CEO, MT): Prioritizes maintaining control over sub-licensing rights and securing a minimum 8% royalty (Paragraph 18).
• James Chen (Lead Negotiator, BigPharma): Focused on acquiring exclusive global rights and minimizing upfront cash outlays in favor of back-ended milestones (Paragraph 20).
• MT Board of Directors: Divided; two VC members demand a deal within 90 days to avoid a down-round, while the founder seeks a long-term partnership (Paragraph 22).

Information Gaps

• Competitor Pipeline: The case does not detail the specific Phase II progress of the rival compound from Gen-Tech (Material Gap).
• Manufacturing Scalability: Data regarding the cost-per-unit at commercial scale is absent (Material Gap).
• BigPharma Internal Priority: It is unclear if MT-101 is the primary or secondary candidate in BigPharma's rare disease portfolio (Material Gap).

2. Strategic Analysis

Prepared by: Market Strategy Consultant

Core Strategic Question

• How can Miracle Therapeutics structure an IP license that secures immediate solvency while capturing the disproportionate upside of a successful Phase III trial?

Structural Analysis

Value Chain Analysis: MT holds the high-value R&D and IP nodes but lacks the downstream capabilities (Regulatory Affairs, Global Distribution, Marketing) required for commercialization. The value of the IP is currently at its highest inflection point—post-Phase IIa success—but will depreciate rapidly if the cash runway terminates before Phase III commencement.

Bargaining Power: MT’s power is constrained by its limited runway (9 months). BigPharma recognizes this liquidity pressure and is using time as a tactical tool to depress the upfront valuation. However, the Orphan Drug designation creates a high barrier to entry, protecting the terminal value of the asset.

Strategic Options

Option 1: The Liquidity-First Exit. Accept the $10M upfront with lower royalties (4-5%) and transfer all sub-licensing rights.
Trade-off: Eliminates insolvency risk but cedes 60% of the projected long-term asset value.
Requirement: Immediate board approval and cessation of internal commercialization planning.

Option 2: The Performance-Linked Hybrid. Propose a $7M upfront payment with aggressive milestones: $15M upon Phase III initiation and $20M upon FDA approval, plus a 7% royalty.
Trade-off: Reduces immediate cash but aligns BigPharma’s incentives with clinical success.
Requirement: Rigorous definition of milestone triggers to prevent "strategic stalling" by the licensee.

Option 3: The Co-Development Bridge. Retain North American rights while licensing Global rights for a $12M fee.
Trade-off: Higher potential return and strategic independence; however, it requires MT to raise additional capital for the US launch.
Requirement: A secondary funding round or a specialized regional partner.

Preliminary Recommendation

MT should pursue Option 2 (Performance-Linked Hybrid). The current $10M offer is a low-ball bid predicated on MT’s weak cash position. By shifting the value to milestones, MT signals confidence in its clinical data and forces BigPharma to pay for de-risked success. MT must insist on a "diligence clause" to ensure BigPharma does not shelf MT-101 in favor of internal candidates.

3. Implementation Roadmap

Prepared by: Operations and Implementation Planner

Critical Path

The transition from a research-focused biotech to an IP-management entity requires a disciplined 90-day execution window to prevent cash exhaustion.

• Days 1-15: Term Sheet Finalization. Lock in the milestone-heavy structure. Key dependency: Board alignment on the minimum acceptable upfront payment ($7M).
• Days 16-45: Technical Transfer Protocol. Document all Phase II data, assays, and CMO relationships. Failure to provide a clean data package will trigger "indemnity drag" in the final contract.
• Days 46-75: Legal and Regulatory Audit. Finalize the "Right to Reference" the Investigational New Drug (IND) filing. This is the critical link for BigPharma to initiate Phase III.
• Days 76-90: Closing and Funding. Transfer of initial funds and formal handover of the regulatory lead to the licensee.

Key Constraints

• Internal Talent Retention: MT’s scientists may exit once the IP is licensed. A retention pool must be carved out from the $7M upfront to keep key personnel through the technical transfer.
• CMO Contract Portability: The Swiss CMO contract must be assignable to BigPharma. If the CMO demands a renegotiation, the Phase III timeline will slip by 4-6 months.

Risk-Adjusted Implementation Strategy

To mitigate the risk of BigPharma delaying the deal to force a lower price, MT must simultaneously open a "Data Room" for a secondary bidder. Even if a second offer is unlikely, the appearance of a competitive process is the only operational lever to accelerate BigPharma’s legal team. Contingency: If the deal is not signed by Day 60, MT must immediately implement a 30% headcount reduction to extend the runway into the following quarter.

4. Executive Review and BLUF

Prepared by: Senior Partner and Executive Reviewer

BLUF

Miracle Therapeutics must execute the licensing deal with BigPharma within 90 days or face a terminal liquidity crisis. The strategic priority is not the upfront cash amount, but the structure of the royalty and milestone payments. Reject the current $10M flat offer. Counter with a $7M upfront payment combined with a 7.5% royalty and a $15M Phase III milestone. This preserves the company's long-term value while providing enough capital to bridge the technical transfer period. Speed is the primary metric of success; any delay past month three cedes all negotiating power to the buyer.

Dangerous Assumption

The analysis assumes BigPharma is negotiating in good faith to commercialize MT-101. There is a significant risk that BigPharma is pursuing a "defensive acquisition"—licensing the IP specifically to prevent it from reaching the market and competing with their existing portfolio. The absence of a "Commercially Reasonable Efforts" clause in the current draft is a fatal flaw.

Unaddressed Risks

• Clinical Concentration Risk (High Probability, High Consequence): MT-101 is the only asset. If Phase III fails, the company has no secondary value. The plan does not account for a "Plan B" asset acquisition or pivot.
• Personnel Flight (Medium Probability, Medium Consequence): The transition from R&D to IP management fundamentally changes the company culture. The loss of Dr. Miller's scientific team during the technical transfer could invalidate the IP's value to the licensee.

Unconsidered Alternative

The team failed to consider a Royalty Monetization strategy. Instead of a traditional license, MT could secure a smaller bridge loan against future royalties from a specialist healthcare fund. This would provide the $5M needed to reach the end of Phase III independently, potentially tripling the company's valuation before a full sale or license is negotiated. This path offers the highest return but carries the highest risk of total loss.

Verdict: APPROVED FOR LEADERSHIP REVIEW